Background: Mutations in the KRAS gene are associated with poor response to epidermal growth factor receptor inhibitors used in the treatment of metastatic colorectal cancer. Factors influencing KRAS test results in tumor specimens include: tumor heterogeneity, sample handling, slide preparation, techniques for tumor enrichment, DNA preparation, assay design and sensitivity. We evaluated comparability and consistency of KRAS test results among five laboratories currently being used to determine KRAS mutation status of metastatic colorectal cancer specimens in a large, multi-center observational study.
Findings

Background and hypothesis
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of metastatic colorectal cancer (CRC). However, these anti-EGFR therapies do not benefit patients whose tumors harbor a KRAS mutation [1] . Genetic testing for the presence of KRAS mutations has been recommended to guide treatment for these patients [2] .
Several factors can influence KRAS mutation testing results in CRC specimens [3] [4] [5] . The purpose of this study was to evaluate comparability and consistency of clinical KRAS test results among laboratories used to determine KRAS mutation status in a large multi-center study. Three commercial laboratories (Genzyme, Clarient, Quest Diagnostics), one clinical academic laboratory (Henry Ford Health System), and one academic research laboratory (Molecular and Medical Genetics, Oregon Health and Science University) were contracted to analyze KRAS mutation status for comparison with previous clinical results. While all five laboratories are Clinical Laboratories Improvement Act (CLIA) certified, they have different sample preparation and mutation detection methods. Our aim was not to certify these laboratories, but to ensure that we could combine data from previously tested clinical samples in our research study.
Methods
Twenty surgical specimens from colon resections were used; eighteen specimens were adenocarcinomas, two were carcinomas. Blocks were reviewed by a pathologist to determine whether the samples were of sufficient quality and quantity for testing, then the samples were de-identified and slides were prepared per individual laboratory specifications. Our intention was to replicate routine sample testing of clinical specimens as much as possible, so sample handling and shipping procedures varied slightly by laboratory. All laboratories used microdissection for tumor enrichment when necessary, but mutation detection methods differed. Methods for each laboratory are described in Table 1 . KRAS test results were compared across labs, and discrepancies were evaluated further. This study was approved by the Institutional Review Boards (IRB) at Kaiser Permanente Colorado and Kaiser Permanente Northwest (the Oregon Health and Science University IRB ceded authority to Kaiser Permanente Northwest).
Results
Twenty formalin-fixed paraffin-embedded (FFPE) CRC samples previously tested clinically for KRAS mutations by sequencing were selected based on mutation status (6 wild-type samples, 8 with codon 12 mutations, and 6 with codon 13 mutations) from two study sites (Kaiser Permanente Colorado and Northwest). Patients ranged in age from 46-85 years; specimens were collected between 2005-2009. We found good agreement in KRAS test results with prior clinical results despite differences in mutation detection methods ( Table 2) . Eighteen of twenty samples (90%) were concordant across all five laboratories, and the mutation type was always consistent.
One laboratory reported a wild-type result for sample 14 which was actually a p.Gly12Asp (G12D) mutation. While this sample was confirmed to contain an acceptable 40% tumor cells, tumor heterogeneity in this sample may have resulted in the variant being present below the pre-determined 20% threshold. A very small electropherogram peak indicating a c.35 G > A change was visible by sequencing indicating p.Gly12Asp mutation, but was not reported because it was below acceptable level of confidence per laboratory protocol.
We also found a discrepancy in sample 6. The initial clinical result was wild-type; two labs reported a mutation in exon 12 p.Gly12Asp, and three labs were consistent with the clinical results (wild-type). We evaluated this discrepancy first by sending additional slides (from the same tumor block) to the two laboratories that reported the mutation. These slides were assigned a new study number to blind the laboratory to the re-testing. Laboratory #2 found the same result (p.Gly12Asp) in the second set of slides, but there was not enough tumor tissue for laboratory #3 to reliably genotype. Next, we used a second FFPE block from the same patient to send a WT  G12D  G12D  WT  WT   7  G12V  G12V  G12V  G12V  G12V  G12V   8  G12D  G12D  G12D  G12D  G12D  G12D   9  G12V  G12V  G12V  G12V  G12V  G12V   10  G12S  G12S  G12S  G12S  G12S  G12S   11  G12V  G12V  G12V  G12V  G12V  G12V   12  G12C  G12C  G12C  G12C  G12C  G12C   13  G12V  G12V  G12V  G12V  G12V  G12V   14  G12D  WT†   G12D  G12D  G12D  G12D   15  G13D  G13D  G13D  G13D  G13D  G13D   16  G13D  G13D  G13D  G13D  G13D  G13D   17  G13D  G13D  G13D  G13D  G13D  G13D   18  G13D  G13D  G13D  G13D  G13D  G13D   19  G13D  G13D  G13D  G13D  G13D  G13D   20  G13D  G13D  G13D  G13D  G13D  G13D *Samples were selected for testing based on these prior clinical results. ** WT: wildtype; G12D: p.Gly12Asp; G12V: p.Gly12Val; G12S: p.Gly12Ser; G13D: p.Gly13Asp. † This laboratory did see some evidence that the sample had a mutation, but was below the confidence threshold. This specimen showed tumor enrichment of approximately 40%, which is at the lower level of detection for this laboratory.
third set of slides with a new study number to laboratories 1-3. Results from this block were concordant at all three laboratories (KRAS wild-type). Finally, we asked laboratories #1 and #2 to "swap" aliquots of the extracted DNA from their original sample 6 FFPE slides. This reanalysis confirmed the initial (discrepant) results at each laboratory. Thus, we conclude that the laboratory results, while different, are accurate for the sample of tissue received at each laboratory. The discrepant results could be due to either true tumor heterogeneity or contamination of the tumor sample with normal tissue. We cannot conclusively determine which of these two scenarios is responsible for our observed results, nor eliminate the possibility that a laboratory error resulting in sample mix-up lead to the discrepant results.
Discussion
We found high concordance of KRAS test results with previously received clinical results across five laboratories, despite differences in laboratory methods. The discordant results observed in two samples are most likely due to sample characteristics rather than to laboratory error. Our study focused only on mutations in codons 12 and 13 of KRAS. These are the most common mutations and are often the only mutations targeted in clinical testing. However, other mutations may have clinical implications and were not included in our study [6, 7] . We limited our study to samples from colon resections. Samples with smaller volume, such as from metastatic sites or biopsy, may not perform as reliably as colectomy specimens if they contain only a small percentage of tumor cells. Several new methods of mutation detection have been reported [3, [8] [9] [10] [11] [12] [13] and may be better suited to samples with a low percentage of tumor cells.
Our results are in agreement with previous studies [8] [9] [10] [11] [12] , including a recent report by Oliner et al. [13] who evaluated five commercial laboratories, one of which (Genzyme) was also included in our study. They tested forty FFPE samples from several tissue procurement providers, whereas our samples were obtained from colectomies performed at our own clinic facilities, previously tested, and used to guide clinical care. Because we were able to select our samples based on mutation status, and thus oversample for the KRAS mutations of interest, our estimate of the agreement across laboratories corresponds to an estimate from an effectively larger sample size. It is reassuring that, while both studies evaluated different commercial laboratories and used slightly different methodologies, both found good agreement across testing facilities.
The commercial and academic-based laboratories included in this study provide reliable test results for common mutations in the KRAS gene from samples with an adequate percentage of tumor cells. Discrepancies observed are likely due to either tumor heterogeneity, or contamination of the tumor sample with normal tissue. Both of these sources of variability are likely to be encountered in the clinical setting, and may have important consequences for treatment decisions.
